We are live on ! Find out more

Aurinia Pharmaceuticals

AUPH

Market cap $2.14B

16.10 USD

-0.01

0.06%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

16.10

0.00

0%

1 day

-0.06%

5 days

0.81%

1 month

4.75%

3 months

1.58%

6 months

8.71%

Year to date

4.89%

1 year

25.98%

5 years

-23.08%

10 years

648.84%

About: Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Employees: 128

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 61.5%

Neutral 38.5%

Negative 0%

Zacks Investment Research

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

AUPH settles voclosporin patent litigation with Teva, delaying potential generic competition in the United States until December 2036.

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are up during Thursday's premarket session as the company has entered into a settlement agreement with Teva Pharmaceutical Industries Ltd. (NYSE:TEVA).

Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug

Aurinia Settles Patent Litigation with Teva

EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Settles Patent Litigation with Teva.

Aurinia Settles Patent Litigation with Teva

Aurinia Pharmaceuticals Doubles Down On Its Pipeline

Aurinia Pharmaceuticals is running the phase 4 PRESERVE trial in lupus nephritis, which tests combinations containing the company's drug Lupkynis. Lupkynis could face potential challenges to its market exclusivity in the not-too-distant future. AUPH is developing aritinercept in four potential indications but doesn't provide much clarity on timelines for further updates.

Aurinia Pharmaceuticals Doubles Down On Its Pipeline

Zacks Investment Research

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

Aurinia Pharmaceuticals (AUPH) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.16 per share a year ago.

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress.

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Top Healthcare Stocks Beyond The Market Rotation Averaging 128% Forward EPS Growth

Healthcare stocks have outperformed in the past month amid a rotation away from the AI trade and other risk-on investments. Global fund managers increased positions in healthcare more than any other sector or asset, according to Bank of America's July survey. In volatile markets, investors tend to pivot to defensive sectors, and healthcare has been a top performer during periods of uncertainty, including ahead of November's U.S. midterm elections.

Top Healthcare Stocks Beyond The Market Rotation Averaging 128% Forward EPS Growth

Playing The Biotech Breakout With Insiders

Biotech stocks are consolidating after a breakout, with bullish insider Wall Street sentiment. AbCellera Biologics and Alpha Cognition stand out for insider buying, revenue growth, and high Seeking Alpha Quant Ratings. ABCL's Phase 2 efficacy readout for ABCL635 in Q3 and ACOG's Zunveyl sales ramp are key catalysts. Both have substantial upside per analyst targets.

Playing The Biotech Breakout With Insiders

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced the initiation of PRESERVE, a Phase 4, multicenter study investigating the combination of LUPKYNIS® and belimumab, obinutuzumab or anifrolumab in patients with lupus nephritis (ClinicalTrials.gov). Planned enrollment is approximately 150 patients across approximately 50 sites in the US. The Study's primary endpoint is the proportion of patients achieving complete renal response (CRR).

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

Zacks Investment Research

Aurinia (AUPH) Upgraded to Strong Buy: Here's Why

Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Aurinia (AUPH) Upgraded to Strong Buy: Here's Why

See News Rankings

Price charts implemented using Lightweight Charts™